Shengbai Oral Liquid (Mixture) was included in the "2018 Clinical Pathway Therapeutic Drug Interpretation: Tumor Disease Volume" anti-tumor Chinese patent medicine

Shengbai Oral Liquid (Mixture) was included in the "2018 Clinical Pathway Therapeutic Drug Interpretation: Tumor Disease Volume" anti-tumor Chinese patent medicine

2018-11-12

PREVOverview of the research on the prevention and treatment of leukopenia after chemoradiotherapy NEXTShengbai Oral Liquid (Mixture) was included in the "2018 Clinical Pathway Therapeutic Drug Interpretation: Blood Diseases Volume" for the treatment of Chinese patent medicines for blood diseases

Hot news

What kind of treatment is needed fo...

How to deal with leukopenia after c...

Should I stop chemotherapy if I h...

Should leukopenia be discontinued i...

Shengbai Oral Liquid (Mixture) w...

Shengbai oral liquid (mixture) was ...

How much do you know about leukopen...

Shengbai Oral Liquid: Progress a...

Service hotline

0724-8886111

Address：3 Fuyao Yi Lu, Doudao District, Jingmen City, Hubei Province, China
Transmissionh：0724-8686500
Email：hbmy_monyan@163.com

ABOUT

About US Corporate culture Company honor Development course
NEWS

Company dynamics Trade news Academic exchanges
H&R

Job development Talent recruitment
PRODUCTS

Drugs in the field of tumor-re Drugs in other fields Health care products
R&D

R&d pipeline R&d progress Patient recruitment
INVESTOR

Latest announcement

COPYRIGHT© 2022 Hubei Mengyang Pharmaceutical Co., LTD. All Rights Reserved E ICP 11014915; Internet Drug Information Service Certificate No. : (E) - Non-business -2016-0032

Technical Support: SUMA